Selected Podcast

MR-LINAC: Which Patients Stand to Benefit Most?

When tumor position and surrounding anatomy change, radiation treatment can adapt—but which patients stand to gain the most? Lucas Serra, MD, director of MR-Guided Radiation Therapy at AHN, explores how MR-LINAC combines MRI visualization with online adaptive planning to more precisely target tumors while limiting radiation exposure to nearby organs. Hear the evidence behind reduced urinary and bowel toxicity in prostate cancer, explore applications in other GU and GI malignancies, and learn the patient-selection considerations that can inform your next referral. 

Learn more about Lucas Serra, MD, MS 


MR-LINAC: Which Patients Stand to Benefit Most?
Featured Speaker:
Lucas Serra, MD, MS

Lucas Serra, MD, MS has expertise in genitourinary (GU) and thoracic malignancies, especially with our MR linac, at Allegheny General Hospital. His impressive background, including an MD and MS from the Jacobs School of Medicine and Biomedical Sciences and a BS from Brown University, along with his experience as Chief Resident at the University of Chicago. 


Learn more about Lucas Serra, MD, MS 

Transcription:
MR-LINAC: Which Patients Stand to Benefit Most?

Melanie Cole, MS (Host): Welcome to AHN Med Talks, an informative resource for physicians across various specialties as we delve into the latest medical insights and best practices, ensuring you stay at the forefront of your field. I'm Melanie Cole. And today, we are highlighting MR-LINAC: How real-time imaging is changing cancer treatment.

Joining me is Dr. Lucas Serra. He's a radiation oncologist at the Allegheny Health Network. Dr. Serra, thank you so much for joining us today. So, what exactly is MR-LINAC, and why is it generating so much attention in oncology?

Dr. Lucas Serra: First, thanks for having me. Happy to talk about this exciting topic. So, I'm the Director of MR-Guided Radiation Therapy at AHN. And so, I'll explain a little bit about this new technology that we're, you know, very privileged to have at AHN. So, what exactly is an MR-LINAC, and how is it different than our more conventional treatment machines?

So, the MR-LINAC combines two technologies in one machine. The first is an MRI scanner, which gives us excellent images of soft tissue. And then the second is the linear accelerator, which is the workhorse of any radiation oncologist. We also call it a LINAC for short. And this produces high energy radiotherapy to treat and cure cancers.

So usually, these technologies have played separate roles. We get an MRI before treatment to understand where the tissue is, where, like, the normal tissue is, where the tumor is. And then, later on, we put the patient on a treatment machine to deliver the radiation, often with X-ray-based imaging, like a CT, like a cone beam CT, or just a simple kV or X-ray.

So, the issue is that the human body isn't static. Things move, bladders fill and empty, bowel loops can shift, and a tumor can change position as the patient breathes. So even if the original treatment plan is excellent, the patient anatomy on a Tuesday, a week later, two weeks later, might not be identical to the anatomy that we saw during the previous week's scan.

And so, the MR-LINAC allows us to obtain MRI images immediately before treatment. And depending on the machine, the treatment technique, sometimes we're able to monitor the target during radiation delivery as well. So, one, it lets us see things that we weren't able to see immediately before and during the treatment. And then, we're also able to adapt the radiation therapy with something called online adaptive radiation therapy. And that's where the radiation oncologist can, on the fly, change the plan based on the anatomy of that day. And so, this allows us to be much more precise and also customize the treatment better, basically, for each patient.

Melanie Cole, MS: So, it really combines MRI imaging and radiation delivery in one system, yes?

Dr. Lucas Serra: Yes, that's exactly right. The MRI scanner is fully integrated with the treatment machine itself, and that lets us, you know, do all these things which we can't on a standard treatment machine.

Melanie Cole, MS: Isn't that fascinating? So, Dr. Serra, when we think of real-time visualization and what that means during treatment, why does seeing the tumor during treatment change your decision-making when we think of adaptive radiation, motion management, which you mentioned, which is so important if a tumor's moving, if it's in the lung due to breathing or digestion, lung, pancreas, prostate, and then tissue-sparing as well? So, explain why this exciting technology helps you to change your decision-making on the fly.

Dr. Lucas Serra: So, the main benefit here is that—let's take prostate cancer, which I treat. The prostate sits between two important organs which can cause side effects. That's the bladder anteriorly, and then posteriorly is the rectum. And bladders can be more full, more empty. You know, the rectum can be more full or empty depending on the day. And on a regular treatment machine, we just, you know, do our best. We can shift where we're giving the dose, but we can't make a new plan on that day with a normal treatment machine.

And so, with the MR-LINAC, one, we're able to see a lot of these soft tissue, these organs much more clearly. And then, on top of that, because of how it's built and also the software that's integrated into it, we're able to completely, basically make a brand-new plan right then and there based on how the patient looks that day. And that lets us, one, get a better plan; and, two, spare the organs better, so we can deliver more precise radiation to the target the prostate or whatever tumor you're treating, and reduce the dose, reduce the side effects ideally to organs at risk like the bladder or the rectum.

Melanie Cole, MS: So, expand just for a second on that, that tissue-sparing portion of all of the benefits of MR-LINAC because as you said, you work with the prostate, and one of the concerns certainly of the patient is those surrounding organs and the toxicity and the possible complications. So, how does MR-LINAC help balance that efficacy and toxicity when we think of all the surrounding tissue and organs?

Dr. Lucas Serra: There's good evidence to support that treating patients on this sort of machine improves toxicity. We have phase III randomized data out of UCLA. It's called the MIRAGE trial. And at least on that trial, they ascribe a lot of the toxicity benefit or the side effect benefit to reducing the margin.

So whenever we treat on any machine, to be honest, we're treating a target. And you can think of the target as a circle. But because things can change day to day, we have to add like a margin, like almost like a little bit extra dose, like a slightly bigger radiation field to account for changes in setup or patient anatomy.

And so, on this machine, because we can visualize the organs that can cause side effects so well and also customize the treatment on the fly, we're able to shrink those margins. For instance on this trial, the MIRAGE trial, they compared 4 millimeters of margin compared to just 2 millimeters of margin, and there was a substantial reduction in both bladder side effects and also rectal side effects. I think the rates were about, like, looking at grade 2 toxicity for urinary outcomes was 50% versus 25%. So, a 50% percent reduction for urinary side effects. And then, for the rectum, it was even better where I think the rates were about 10% versus maybe 2.5%, so four times less. So, it's like a fourth of what you get on the normal machine. So, that seems pretty impactful.

Melanie Cole, MS: Wow. So, which patients may benefit most from MR-guided radiation? You work with prostate cancer patients. Tell us a little bit about patient selection, whether we're talking about other cancer situations or prostate. Tell us if there are some contraindications, whether it is body type, obesity, you know, comorbid conditions. Are there any contraindications?

Dr. Lucas Serra: So, I'll answer the first part: which cancers or which patients benefit the most? I would say that, broadly speaking, this is still evolving. This is a pretty new technology only really being adopted within the first few years. AHN is lucky that I think we were the sixth center in the US to get this technology. I want to say there's maybe about 15 centers that offer the MR-LINAC. In terms of the types of tumors that we're treating, typically, we think of GU and GI cancers. So, that would be like prostate predominantly. And then, rectal cancers, we're treating as well, liver cancers and then pancreatic cancers. These are cancers where we're trying to give a high dose to a target that is surrounded by soft tissue organs that are at risk and we're trying to really focus the radiation. And so, that's really where the benefit is for these types of patients.

In terms of who is not eligible, so what are the downsides? So, this technology is amazing because the imaging is better, the customizability is better, but there's some downsides. So, there's more time on the table. And also, because it's an MRI scanner, patients who are claustrophobic may not tolerate it very well. We can give medications like Ativan to make the experience better and tolerable for those patients, but someone severely claustrophobic, it's not going to be a good fit for them, and they would be well-served with a standard LINAC.

There's also size criteria. So, you're right to mention obesity and things like that. I would say 95% of the patients that we've seen have been able to fit in the scanner. But because it's an MRI scanner, there's a bore, right? So, there's like a circumference that the patient has to fit into.

And then, also, there's extra stuff because we're giving radiotherapy, sometimes there's things to keep them still and coils and things like that. And so, before we even put the patient on the machine, we have a way of checking if they will fit or their midsection will fit basically in the machine.

So, those are really the big downsides. So, longer treatment time, longer time on the table, claustrophobia. And then, there is certain patients who are not the correct size for the treatment machine. So, those are really the big downsides. And then, of course, because it's an MRI, certain metal objects or metal joint replacements and things like that may make a patient ineligible, but we screen those patients. And then, pacemakers is also a no-go, because that requires MR-safe monitoring technology, which we don't currently have.

Melanie Cole, MS: Dr. Serra, you've given us so much to think about with these, but why is MR-guided prostate radiation such a differentiator. You've talked about precision targeting. But for the patient and the benefits for them, fewer treatment visits and convenience, tell us a little bit about what makes this so special.

Dr. Lucas Serra: The visit time is also important. So typically, we treat patients in only five treatments, usually Tuesday, Thursday, Tuesday, Thursday, Tuesday. So, it is shorter. I would say if you do a more hypofractionated route, you're looking at 20 to 28 treatments. So, that's a bonus for the five treatments.

In addition to that, there's, like I mentioned, that MIRAGE trial, there's high-quality evidence, phase III randomized evidence to show that we are meaningfully changing outcomes for these patients. And I mentioned the reduction in both urinary side effects and bowel side effects. Those numbers I gave, those were for acute toxicity. So, that is short-term side effects. But that has also translated. They did a recent analysis, the recent report on the outcomes, that has translated into a reduction in late side effects, which is very impactful for patients. So, that means that they're not getting up as much after radiation to go pee. They don't have as much urgency. And the same applies to their bowels as well, where they might have less loose stools, less urgency, less frequency for both those things. And then, there's also potential benefit for sexual side effects. So, there's also the potential reduction for that. That hasn't been quite as well-established as the other two endpoints, but there is some data to suggest that as well.

Melanie Cole, MS: What does the future look like of radiation-oncology when we think of this amazing technology and adding more tools to your armamentarium of treatment options and therapies? What's exciting? What does the future look like to you?

Dr. Lucas Serra: I think this is the future of radiation oncology. If you talk with a lot of people in the field, the idea of adaptive radiation is a very attractive one for a lot of the things that I've mentioned.

And in addition to that, some of the other technologies we were hoping would help for prostate cancer. For instance, I have patients coming to me asking about proton therapy. And just because of how the physics works on that, you know, we thought that there would be a benefit. However, there's now high quality to show that there is no benefit for proton radiation versus photon-based treatments like the MRI-LINAC or a standard LINAC.

And so, this is really the forefront. This is adaptive therapy, online adaptive therapy, the MRI-LINAC, being able to see better and customize treatment on the fly. That is really the future of radiotherapy. And if you talk with some people in the field, they see a future where every fraction and many disease sites, not just the ones that I've listed, are eligible for and benefit from this, you know, more focused, more customizable form of radiation. So, that's very exciting.

In addition to that, this is more, I would say, in the research domain and has been less proven, but you can imagine if we're getting MRIs, for every treatment, that can tell us something about how the treatment's working and about the patient's prognosis or how to tailor the treatment even more. And I'm talking about radiomics and biomarkers and things like that. And so, that's also very exciting, and that's being actively investigated.

Melanie Cole, MS: That is exciting that it's happening with each therapy. So, you can see what's working. That's really cool, Dr. Serra. As we wrap up, when you think of what referrals might look like five years from now, I'd like you to speak about that and what referring physicians should know before sending a patient to you at this point.

Dr. Lucas Serra: I think, at least right now, the main sort of patients that would benefit the most from this sort of treatment is definitely prostate, rectal, pancreas. So, we're talking about GU and GI malignancies. And then, we also treat recurrent disease. So, that means prostate recurrence or recurrence in the seminal vesicles or recurrence in a lymph node. Those patients also benefit. The guidelines also recommend, especially if those recurrences are near soft tissue structures like bowel, that they actually are best served by adaptive therapy like the MRI-LINAC. And then, we're also treating more esoteric things like oligometastatic disease. That is just one or two mets in the patient's body. Those are all good things to refer to the MRI-LINAC where the patient would probably benefit from this specific treatment.

In the future, we hope to expand this, so this is actively being looked at. And I hope to write a protocol soon trying to treat, you know, kidney cancer, that's renal cell carcinoma using the MRI-LINAC, just because the kidneys and tumors of the kidney can be very close to bowel. And our hope is that we can make the treatment more precise for those patients as well. But that's an active area of investigation. But I anticipate in the next five-ish years that we'll have more and better indications for who to treat with the MRI-LINAC. But it's very exciting, I'll say. It's a very cool technology, and the patients are pretty happy with it.

Melanie Cole, MS: Wow. It is a very cool technology, and that was an excellent discussion. Thank you so much, Dr. Serra, for joining us today and really sharing your unique expertise in something that other providers really—very exciting—need to learn about, because that is really as we look toward the future. This is the wave of the future, and you're telling us about it. So, I hope you'll join us again and let us know if you do write some protocols. So, thank you again. To learn more or to refer your patient, please call 412-578-HOPE. That's 412-578-4673 or visit findcare.ahn.org. Thank you so much for listening to this edition of AHN Med Talks with the Allegheny Health Network. I'm Melanie Cole.